JUBLPHARMA — Jubilant Pharmova Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Jubilant Pharmova, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2019 March 31st	C2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	91,108	59,758	60,985	61,302	62,817
Cost of Revenue
Gross Profit	52,896	43,275	43,451	43,432	40,589
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	80,090	48,004	50,011	53,057	61,087
Operating Profit	11,018	11,754	10,974	8,245	1,730
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9,038	10,129	8,711	6,304	278
Provision for Income Taxes
Net Income After Taxes	5,770	6,060	5,739	4,130	-649
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	5,745	8,982	8,359	4,139	-610
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	5,745	8,982	8,359	4,139	-610
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	49	40.4	38.3	26.1	5.6
Dividends per Share